GSTM1 and NAT2 polymorphisms and colon, lung and bladder cancer risk: a case-control study.

BACKGROUND Glutathione S-transferase M1 (GSTM1) and N-acetyltransferase-2 (NAT2) are phase II enzymes involved in the metabolism of xenobiotics and whose polymorphisms have been related to individual cancer risks. PATIENTS AND METHODS A case-control study was performed including 92 colon, 75 lung and 23 bladder cancer patients and 121 corresponding controls to verify the existence of an association between the main genetic polymorphisms of GSTM1 and NAT2 and the risk to develop cancer. Genomic DNA, isolated from 5 mL whole blood, was used to study GSTM1 and NAT2 polymorphisms using multiplex PCR and a PCR-RFLP technique, respectively. RESULTS GSTM1 homozygous null genotype was associated with an increased risk of colon cancer, especially in females and in younger patients. For NAT2 gene, the results suggest a role for the low acetylator phenotype in the development of colon and lung cancer, especially in females. In bladder cancer patients two rare NAT2 genotypes were found at a higher frequency compared with all the other groups. CONCLUSION The results do not suggest a different distribution of GSTM1 and NAT2 polymorphisms in the studied population compared to those reported for other Caucasian populations and warrant further studies in order to evaluate their potential relationship with individual cancer risks.

[1]  John D Potter,et al.  Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. , 2008, JAMA.

[2]  U. Meyer,et al.  The role of the human acetylation polymorphism in the metabolic activation of the food carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline (IQ). , 1992, Carcinogenesis.

[3]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[4]  W. Weber,et al.  N-acetylation pharmacogenetics. , 1985, Pharmacological reviews.

[5]  A. Cittadini,et al.  Glutathione S-transferase (GST) polymorphisms as risk factors for cancer in a highly homogeneous population from southern Italy. , 2002, Anticancer research.

[6]  Nebert Dw.  Polymorphisms in drug-metabolizing enzymes : What is their clinical relevance and why do they exist? , 1997 .

[7]  U. Meyer,et al.  Molecular mechanisms of genetic polymorphisms of drug metabolism. , 1997, Annual review of pharmacology and toxicology.

[8]  David B. Goldstein,et al.  Population genetic structure of variable drug response , 2001, Nature Genetics.

[9]  K. Osawa,et al.  NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status. , 2007, Asian Pacific journal of cancer prevention : APJCP.

[10]  R. Pero,et al.  A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. , 1986, Carcinogenesis.

[11]  T. Rushmore,et al.  Glutathione S-transferases, structure, regulation, and therapeutic implications. , 1993, The Journal of biological chemistry.

[12]  P. Vineis,et al.  Genetic metabolic polymorphisms and the risk of cancer: a review of the literature. , 1996, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[13]  J. Sándor,et al.  Polymorphisms of glutathione-S-transferase and arylamine N-acetyltransferase enzymes and susceptibility to colorectal cancer. , 2004, Anticancer research.

[14]  H. Chiou,et al.  Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer , 1999, British Journal of Cancer.

[15]  P. Vineis,et al.  Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. , 1991, Pharmacogenetics.

[16]  K. Osawa,et al.  Association of CYP1A1, CYP1A2, GSTM1 and NAT2 gene polymorphisms with colorectal cancer and smoking. , 2007, Asian Pacific journal of cancer prevention : APJCP.

[17]  Gillian Smith,et al.  Metabolic polymorphisms and cancer susceptibility. , 1995, Cancer surveys.

[18]  S. Anttila,et al.  Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility--a review. , 1995, Gene.

[19]  F. Perera.  Molecular epidemiology: on the path to prevention? , 2000, Journal of the National Cancer Institute.

[20]  W. Pearson,et al.  Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Jack A. Taylor,et al.  Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. , 1993, Carcinogenesis.

[22]  H. Brenner,et al.  Effect of NAT1 and NAT2 Genetic Polymorphisms on Colorectal Cancer Risk Associated with Exposure to Tobacco Smoke and Meat Consumption , 2006, Cancer Epidemiology Biomarkers & Prevention.

[23]  H. Okkels,et al.  Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.